REPORT ID 13382

EMEA (Europe, Middle East and Africa) Cardiovascular Drugs Market Report 2017

Publish Date
21-Nov-17
Pages
114
Format
Electronic (PDF)

In this report, the EMEA Cardiovascular Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Cardiovascular Drugs for these regions, from 2012 to 2022 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Cardiovascular Drugs market competition by top manufacturers/players, with Cardiovascular Drugs sales volume (K Units), price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including
    AstraZeneca
    Pfizer Inc.
    Novartis AG
    Merck & Co., Inc.
    Bristol-Myers Squibb Company
    Bayer AG
    Sanofi
    Boehringer Ingelheim GmbH
    F. Hoffmann-La Roche Ltd
    Abbott Laboratories
    Gilead Sciences, Inc.
    Johnson & Johnson
    Astellas Pharma, Inc.
    Eli Lilly and Company
    Otsuka Holdings Co., Ltd.
    Takeda Pharmaceutical Company Limited

On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into
    Anti hyperlipidemics
    Antihypertensive
    Anti-coagulants
    Antifibrinolytic
    Antiarrhythmic
    Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Cardiovascular Drugs for each application, including
    Retail Pharmacies
    Hospital Pharmacies
    Online Pharmacies

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) Cardiovascular Drugs Market Report 2017
1 Cardiovascular Drugs Overview
    1.1 Product Overview and Scope of Cardiovascular Drugs
    1.2 Classification of Cardiovascular Drugs
        1.2.1 EMEA Cardiovascular Drugs Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 EMEA Cardiovascular Drugs Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 Anti hyperlipidemics
        1.2.4 Antihypertensive
        1.2.5 Anti-coagulants
        1.2.6 Antifibrinolytic
        1.2.7 Antiarrhythmic
        1.2.8 Others
    1.3 EMEA Cardiovascular Drugs Market by Application/End Users
        1.3.1 EMEA Cardiovascular Drugs Sales (Volume) and Market Share Comparison by Application (2012-2022
        1.3.2 Retail Pharmacies
        1.3.3 Hospital Pharmacies
        1.3.4 Online Pharmacies
    1.4 EMEA Cardiovascular Drugs Market by Region
        1.4.1 EMEA Cardiovascular Drugs Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 Europe Status and Prospect (2012-2022)
        1.4.3 Middle East Status and Prospect (2012-2022)
        1.4.4 Africa Status and Prospect (2012-2022)
    1.5 EMEA Market Size (Value and Volume) of Cardiovascular Drugs (2012-2022)
        1.5.1 EMEA Cardiovascular Drugs Sales and Growth Rate (2012-2022)
        1.5.2 EMEA Cardiovascular Drugs Revenue and Growth Rate (2012-2022)

2 EMEA Cardiovascular Drugs Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Cardiovascular Drugs Market Competition by Players/Manufacturers
        2.1.1 EMEA Cardiovascular Drugs Sales Volume and Market Share of Major Players (2012-2017)
        2.1.2 EMEA Cardiovascular Drugs Revenue and Share by Players (2012-2017)
        2.1.3 EMEA Cardiovascular Drugs Sale Price by Players (2012-2017)
    2.2 EMEA Cardiovascular Drugs (Volume and Value) by Type/Product Category
        2.2.1 EMEA Cardiovascular Drugs Sales and Market Share by Type (2012-2017)
        2.2.2 EMEA Cardiovascular Drugs Revenue and Market Share by Type (2012-2017)
        2.2.3 EMEA Cardiovascular Drugs Sale Price by Type (2012-2017)
    2.3 EMEA Cardiovascular Drugs (Volume) by Application
    2.4 EMEA Cardiovascular Drugs (Volume and Value) by Region
        2.4.1 EMEA Cardiovascular Drugs Sales and Market Share by Region (2012-2017)
        2.4.2 EMEA Cardiovascular Drugs Revenue and Market Share by Region (2012-2017)
        2.4.3 EMEA Cardiovascular Drugs Sales Price by Region (2012-2017)

3 Europe Cardiovascular Drugs (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Cardiovascular Drugs Sales and Value (2012-2017)
        3.1.1 Europe Cardiovascular Drugs Sales Volume and Growth Rate (2012-2017)
        3.1.2 Europe Cardiovascular Drugs Revenue and Growth Rate (2012-2017)
    3.2 Europe Cardiovascular Drugs Sales and Market Share by Type
    3.3 Europe Cardiovascular Drugs Sales and Market Share by Application
    3.4 Europe Cardiovascular Drugs Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Cardiovascular Drugs Sales Volume by Countries (2012-2017)
        3.4.2 Europe Cardiovascular Drugs Revenue by Countries (2012-2017)
        3.4.3 Germany Cardiovascular Drugs Sales and Growth Rate (2012-2017)
        3.4.4 France Cardiovascular Drugs Sales and Growth Rate (2012-2017)
        3.4.5 UK Cardiovascular Drugs Sales and Growth Rate (2012-2017)
        3.4.6 Russia Cardiovascular Drugs Sales and Growth Rate (2012-2017)
        3.4.7 Italy Cardiovascular Drugs Sales and Growth Rate (2012-2017)
        3.4.8 Benelux Cardiovascular Drugs Sales and Growth Rate (2012-2017)

4 Middle East Cardiovascular Drugs (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Cardiovascular Drugs Sales and Value (2012-2017)
        4.1.1 Middle East Cardiovascular Drugs Sales Volume and Growth Rate (2012-2017)
        4.1.2 Middle East Cardiovascular Drugs Revenue and Growth Rate (2012-2017)
    4.2 Middle East Cardiovascular Drugs Sales and Market Share by Type
    4.3 Middle East Cardiovascular Drugs Sales and Market Share by Application
    4.4 Middle East Cardiovascular Drugs Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Cardiovascular Drugs Sales Volume by Countries (2012-2017)
        4.4.2 Middle East Cardiovascular Drugs Revenue by Countries (2012-2017)
        4.4.3 Saudi Arabia Cardiovascular Drugs Sales and Growth Rate (2012-2017)
        4.4.4 Israel Cardiovascular Drugs Sales and Growth Rate (2012-2017)
        4.4.5 UAE Cardiovascular Drugs Sales and Growth Rate (2012-2017)
        4.4.6 Iran Cardiovascular Drugs Sales and Growth Rate (2012-2017)

5 Africa Cardiovascular Drugs (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Cardiovascular Drugs Sales and Value (2012-2017)
        5.1.1 Africa Cardiovascular Drugs Sales Volume and Growth Rate (2012-2017)
        5.1.2 Africa Cardiovascular Drugs Revenue and Growth Rate (2012-2017)
    5.2 Africa Cardiovascular Drugs Sales and Market Share by Type
    5.3 Africa Cardiovascular Drugs Sales and Market Share by Application
    5.4 Africa Cardiovascular Drugs Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Cardiovascular Drugs Sales Volume by Countries (2012-2017)
        5.4.2 Africa Cardiovascular Drugs Revenue by Countries (2012-2017)
        5.4.3 South Africa Cardiovascular Drugs Sales and Growth Rate (2012-2017)
        5.4.4 Nigeria Cardiovascular Drugs Sales and Growth Rate (2012-2017)
        5.4.5 Egypt Cardiovascular Drugs Sales and Growth Rate (2012-2017)
        5.4.6 Algeria Cardiovascular Drugs Sales and Growth Rate (2012-2017)

6 EMEA Cardiovascular Drugs Manufacturers/Players Profiles and Sales Data
    6.1 AstraZeneca
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Cardiovascular Drugs Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 AstraZeneca Cardiovascular Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Pfizer Inc.
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Cardiovascular Drugs Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Pfizer Inc. Cardiovascular Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Novartis AG
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Cardiovascular Drugs Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Novartis AG Cardiovascular Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Merck & Co., Inc.
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Cardiovascular Drugs Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Merck & Co., Inc. Cardiovascular Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Bristol-Myers Squibb Company
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Cardiovascular Drugs Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Bristol-Myers Squibb Company Cardiovascular Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Bayer AG
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Cardiovascular Drugs Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Bayer AG Cardiovascular Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Sanofi
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Cardiovascular Drugs Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Sanofi Cardiovascular Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Boehringer Ingelheim GmbH
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 Cardiovascular Drugs Product Type, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Boehringer Ingelheim GmbH Cardiovascular Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 F. Hoffmann-La Roche Ltd
        6.9.1 Company Basic Information, Manufacturing Base and Competitors
        6.9.2 Cardiovascular Drugs Product Type, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 F. Hoffmann-La Roche Ltd Cardiovascular Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Abbott Laboratories
        6.10.1 Company Basic Information, Manufacturing Base and Competitors
        6.10.2 Cardiovascular Drugs Product Type, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Abbott Laboratories Cardiovascular Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview
    6.11 Gilead Sciences, Inc.
    6.12 Johnson & Johnson
    6.13 Astellas Pharma, Inc.
    6.14 Eli Lilly and Company
    6.15 Otsuka Holdings Co., Ltd.
    6.16 Takeda Pharmaceutical Company Limited

7 Cardiovascular Drugs Manufacturing Cost Analysis
    7.1 Cardiovascular Drugs Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Cardiovascular Drugs

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Cardiovascular Drugs Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Cardiovascular Drugs Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA Cardiovascular Drugs Market Forecast (2017-2022)
    11.1 EMEA Cardiovascular Drugs Sales, Revenue and Price Forecast (2017-2022)
        11.1.1 EMEA Cardiovascular Drugs Sales and Growth Rate Forecast (2017-2022)
        11.1.2 EMEA Cardiovascular Drugs Revenue and Growth Rate Forecast (2017-2022)
        11.1.3 EMEA Cardiovascular Drugs Price and Trend Forecast (2017-2022)
    11.2 EMEA Cardiovascular Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.3 Europe Cardiovascular Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.4 Middle Eastt Cardiovascular Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.5 Africa Cardiovascular Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.6 EMEA Cardiovascular Drugs Sales Forecast by Type (2017-2022)
    11.7 EMEA Cardiovascular Drugs Sales Forecast by Application (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer